Actively Recruiting

Colorectal Cancer Clinical Trials

Find recruiting clinical trials for colorectal cancer in the UK � colon, rectal, and bowel cancer subtypes. See your treatment pathway and where trials fit in.

Free to use � Live data from ClinicalTrials.gov � Updated hourly

🎯 Smart Matcher — Find Trials For You

Answer a few questions about your condition and we'll match you to the most relevant clinical trials.

Find My Matches →

Colorectal Cancer Treatment Pathway

See where clinical trials fit into your treatment journey

1st Line (Metastatic)

Initial systemic treatment for metastatic disease

Standard: FOLFOX or FOLFIRI + Bevacizumab or Cetuximab (RAS wild-type)

2nd Line

After progression on 1st-line therapy

Standard: Switch chemotherapy backbone + targeted therapy

3rd Line + / Refractory

After multiple lines � clinical trials are especially important

Standard: Regorafenib, TAS-102, or clinical trial

Key Biomarkers

RAS / BRAF Mutation Status

RAS and BRAF mutations affect which targeted therapies will work. Anti-EGFR therapies (cetuximab, panitumumab) only work in RAS wild-type tumours. BRAF V600E mutations indicate poorer prognosis and specific treatment approaches.

MSI / dMMR Status

Microsatellite instability (MSI-H) or deficient mismatch repair (dMMR) occurs in about 5% of metastatic CRC. These patients respond exceptionally well to immunotherapy (pembrolizumab).

HER2 Amplification

About 3-5% of CRC tumours overexpress HER2. Emerging evidence supports HER2-targeted combinations (trastuzumab + pertuzumab or trastuzumab + lapatinib) in this subgroup.

Search Colorectal Cancer Trials

Loading trials from ClinicalTrials.gov...

Frequently Asked Questions

Yes. Trials for early-stage disease investigate neoadjuvant approaches, shorter courses of chemotherapy, organ-preserving strategies, and surveillance protocols after treatment.

Current trials study immunotherapy for MSI-H tumours, novel combinations for KRAS-mutant disease, liquid biopsy-guided treatment, and targeted therapies for specific molecular subtypes.

Absolutely. Most colorectal cancer trials target metastatic or advanced disease. Options include first-line combination studies, later-line targeted therapies, and immunotherapy for MSI-H patients.

How to Join a Colorectal Cancer Clinical Trial

1

Search

Use our search above to find trials that match your condition and location. Review the eligibility criteria carefully.

2

Discuss

Talk to your GP or specialist about any trials you are interested in. They can help determine if a trial is appropriate for you.

3

Contact

Reach out to the trial team directly using the contact information on the ClinicalTrials.gov listing. They will guide you through screening.

4

Enrol

If you meet the criteria and decide to participate, you will go through informed consent and begin the trial process.

Related Comparisons

🗺️ Related Pathway: Oncology & Cancer Pathway